The idea that pharmaceutical companies focus on treatment at the expense of cures is inaccurate. Not because they’ve decided to put the greater good ahead of profits, but because they realized they could price breakthrough cures to match the customer LTV of chronic treatments.

Novartis recently won approval for a cure to a rare genetic disorder, priced at two million dollars: https://www.reuters.com/article/us-novartis-genetherapy/nova...